IL156505A0 - Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient - Google Patents

Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient

Info

Publication number
IL156505A0
IL156505A0 IL15650501A IL15650501A IL156505A0 IL 156505 A0 IL156505 A0 IL 156505A0 IL 15650501 A IL15650501 A IL 15650501A IL 15650501 A IL15650501 A IL 15650501A IL 156505 A0 IL156505 A0 IL 156505A0
Authority
IL
Israel
Prior art keywords
agent
derivative
compound
formula
active ingredient
Prior art date
Application number
IL15650501A
Other languages
English (en)
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of IL156505A0 publication Critical patent/IL156505A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL15650501A 2000-12-25 2001-12-21 Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient IL156505A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000392723 2000-12-25
PCT/JP2001/011255 WO2002051820A1 (fr) 2000-12-25 2001-12-21 Composes derives de dihydronaphtalene et medicaments utilisant ces composes comme ingredient actif

Publications (1)

Publication Number Publication Date
IL156505A0 true IL156505A0 (en) 2004-01-04

Family

ID=18858667

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15650501A IL156505A0 (en) 2000-12-25 2001-12-21 Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient
IL156505A IL156505A (en) 2000-12-25 2003-06-18 Derivatives of dehydro-naphthalene and drugs containing these compounds as the active ingredient

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL156505A IL156505A (en) 2000-12-25 2003-06-18 Derivatives of dehydro-naphthalene and drugs containing these compounds as the active ingredient

Country Status (23)

Country Link
US (2) US7220864B2 (fr)
EP (2) EP1726586A1 (fr)
JP (1) JP3491635B2 (fr)
KR (2) KR100635315B1 (fr)
CN (1) CN100357280C (fr)
AT (1) ATE370130T1 (fr)
BR (1) BR0116526A (fr)
CA (1) CA2432211C (fr)
CZ (1) CZ20031772A3 (fr)
DE (1) DE60130031T2 (fr)
DK (1) DK1354879T3 (fr)
ES (1) ES2291378T3 (fr)
HU (1) HUP0303636A3 (fr)
IL (2) IL156505A0 (fr)
MX (1) MXPA03005763A (fr)
NO (1) NO327132B1 (fr)
NZ (1) NZ526687A (fr)
PL (1) PL207798B1 (fr)
PT (1) PT1354879E (fr)
RU (1) RU2268262C2 (fr)
TW (1) TWI235748B (fr)
WO (1) WO2002051820A1 (fr)
ZA (1) ZA200304913B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375093B2 (en) 2002-07-05 2008-05-20 Intrexon Corporation Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
AU2003263814A1 (en) * 2002-07-26 2004-02-16 Bayer Pharmaceuticals Corporation Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
JP2005104951A (ja) * 2003-01-17 2005-04-21 Kirin Brewery Co Ltd 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品
US7148246B2 (en) 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
DE10308355A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE10308351A1 (de) * 2003-02-27 2004-11-25 Aventis Pharma Deutschland Gmbh 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308354A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Cycloalkylderivate mit biosteren Carbonsäure-Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10308353A1 (de) * 2003-02-27 2004-12-02 Aventis Pharma Deutschland Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JPWO2005103017A1 (ja) * 2004-04-20 2008-03-13 小野薬品工業株式会社 難溶性薬物の比表面積増大方法
CN101304984A (zh) * 2005-11-07 2008-11-12 Irm责任有限公司 唑和噻唑ppar调节剂
JP5718233B2 (ja) 2008-10-20 2015-05-13 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 甲状腺刺激ホルモン受容体（ｔｓｈｒ）の低分子量アゴニスト
EP2563777A4 (fr) 2010-04-08 2013-09-04 Us Health Agonistes inverses et antagonistes neutres pour récepteur du tsh
US20130158063A1 (en) * 2010-08-24 2013-06-20 Georgetown University Compounds, Compositions and Methods Related to PPAR Antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4317320A1 (de) * 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
AU8750298A (en) 1997-08-28 1999-03-22 Ono Pharmaceutical Co. Ltd. Peroxisome proliferator-activated receptor controllers

Also Published As

Publication number Publication date
US7220864B2 (en) 2007-05-22
DE60130031D1 (de) 2007-09-27
EP1354879B1 (fr) 2007-08-15
EP1354879A1 (fr) 2003-10-22
IL156505A (en) 2009-09-22
CN1489582A (zh) 2004-04-14
JPWO2002051820A1 (ja) 2004-04-22
NO327132B1 (no) 2009-04-27
ATE370130T1 (de) 2007-09-15
TWI235748B (en) 2005-07-11
RU2268262C2 (ru) 2006-01-20
EP1726586A1 (fr) 2006-11-29
KR20030064871A (ko) 2003-08-02
US20040138213A1 (en) 2004-07-15
MXPA03005763A (es) 2004-05-03
DE60130031T2 (de) 2008-05-15
CN100357280C (zh) 2007-12-26
PL207798B1 (pl) 2011-02-28
KR20060083436A (ko) 2006-07-20
JP3491635B2 (ja) 2004-01-26
PT1354879E (pt) 2007-10-29
CZ20031772A3 (cs) 2003-11-12
NO20032895L (no) 2003-08-25
CA2432211C (fr) 2010-07-13
NO20032895D0 (no) 2003-06-23
WO2002051820A1 (fr) 2002-07-04
HUP0303636A2 (hu) 2004-03-01
CA2432211A1 (fr) 2002-07-04
EP1354879A4 (fr) 2004-09-22
ES2291378T3 (es) 2008-03-01
KR100718906B1 (ko) 2007-05-18
US20060287304A1 (en) 2006-12-21
KR100635315B1 (ko) 2006-10-18
DK1354879T3 (da) 2007-12-17
NZ526687A (en) 2004-08-27
ZA200304913B (en) 2004-01-22
PL363583A1 (en) 2004-11-29
BR0116526A (pt) 2004-07-06
HUP0303636A3 (en) 2006-02-28

Similar Documents

Publication Publication Date Title
EP1067109A4 (fr) Derives d'acide carboxylique et medicaments contenant ces derives comme principe actif
IL156505A0 (en) Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient
WO2001096311A3 (fr) Inhibiteurs de la hmg-coa reductase et procede associe
EP1122255A4 (fr) Derives d'acide carboxylique et medicaments contenant ces derives en tant que principe actif
MY142551A (en) Substituted diaryl heterocycles, process for their preparation and their use as medicaments
UA104987C2 (uk) Похідні 3-(2,6-диметилбензилокси)фенілоцтової кислоти
JP2008521831A5 (fr)
WO2002060388A3 (fr) Acyl-sulfamides pour le traitement de l'obesite, du diabete et des troubles lipidiques
EP1088824A3 (fr) Amides de pyrrole bicycliques comme inhibiteurs du glycogène phosphorylase
DE69840510D1 (de) Medizinische zusammensetzungen mit cholesterin erniedrigender wirkung
DK0543662T3 (fr)
RU99108731A (ru) Применение аналогов сибутрамина для снижения уровней липидов
CA2400486A1 (fr) Ligands derives d'aniline pour le recepteur thyroidien
EP1108713A4 (fr) Derives d'acide carboxylique et medicaments dont ils sont le principe actif
PT1213296E (pt) Derivados de glucopiranosiloxipirazole composicoes medicas que os contem e intermediarios na sua producao
WO2007059372A3 (fr) Utilisation de chloroquine en vue de traiter un syndrome metabolique
YU63301A (sh) Oksaminske kiseline i njihovi derivati kao ligandi tiroidnog receptora
BR0101527A (pt) Ligandos de receptores de tiróide
BR0016064A (pt) Compostos heterocìclicos e seus sais e uso medicinal dos mesmos
EP1295875A4 (fr) Composes heterocycliques
EP1602642A4 (fr) Composes derives d'imino ether et medicaments renfermant ces composes comme principe actif
WO2003042194A1 (fr) Composes derives d'acide carboxylique et medicaments contenant ces composes en tant que principe actif
EP1569904A4 (fr) Derives d'acides arylalcanoiques substitues servant d'agonistes de ppar pan ayant une forte activite antihyperglycemique et antihyperlipidemique
CA2365085A1 (fr) Agents therapeutiques contre le diabete
ES2173049A2 (es) Monoestrer de acido graso y estrogeno como agente antidiabetico e hipolipemiante.